Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Próba obrazowania metodą rezonansu magnetycznego serca (CorCMR) w dławicy wieńcowej (CorCMR)

15 listopada 2026 zaktualizowane przez: Colin Berry, NHS National Waiting Times Centre Board

Kliniczna przydatność obrazowania rezonansu magnetycznego serca u pacjentów z dławicą piersiową, ale bez obturacyjnej choroby wieńcowej (CorCMR): badanie diagnostyczne i zagnieżdżona randomizowana próba

Anginal symptoms due to ischaemia with no obstructive coronary arteries (INOCA) is a common clinical problem, however, diagnosis and onward management is heterogeneous, and prognosis is affected. Recent advances in quantifying myocardial blood flow using stress perfusion cardiac magnetic resonance imaging (CMR) has potential for accurate detection coronary microvascular dysfunction.

The CorCMR diagnostic study involves stress perfusion CMR in patients with suspected INOCA to clarify the prevalence of subgroups of patients with underlying problems, such as microvascular disease or undisclosed obstructive coronary artery disease, that might explain their anginal symptoms.

A nested, prospective, randomised, controlled, double-blind trial will determine whether stratified medical therapy guided by the results of the stress perfusion CMR improves symptoms, well-being, cardiovascular risk and health and economic outcomes.

Przegląd badań

Status

Aktywny, nie rekrutujący

Warunki

Interwencja / Leczenie

Szczegółowy opis

Background:

There are approximately 2 million men and women living with angina in the UK. In 2014, there were ~247,000 coronary angiograms performed, mostly for the investigation of known or suspected angina. However, obstructive CAD is detected in only 1 in 2 patients. The explanation for the cause(s) of the chest pain are often unclear. Microvascular or vasospastic angina may be one explanation.

Adjunctive tests of coronary artery function to diagnose these problems are rarely used during coronary angiography in the NHS, meaning that patient management may be empirical and heterogeneous. The lack of adoption of these novel tests in the NHS reflects key gaps in the clinical evidence. It is these gaps, coupled with the increasing adoption of anatomical coronary artery imaging with CT coronary angiography (CTCA), which stimulate this research. In recent large clinical trials, CT coronary angiography has been shown not to reduce the rate of invasive angiography. In fact, compared to standard care based on stress testing, CTCA is associated with less improvement in anginal symptoms and in quality of life (PUBMED ID: 28246175). Anatomical tests, such as CTCA and invasive angiography, do not provide information on myocardial blood flow. New evidence that addresses these gaps might inform therapy development and future trials.

Current gaps in evidence and guidelines point to a problem of unmet need in the NHS care pathway. Stress perfusion CMR has potential diagnostic value for microvascular disease, but whether it might discriminate clinical endotypes in a relatively unselected population of patients in daily practice, is uncertain. Further, access to stress perfusion CMR varies widely not least because evidence from randomised trials supporting clinical and economic benefits from a CMR-guided approach is lacking. CorCMR is a clinical strategy trial that is designed to address this evidence gap.

Hypothesis:

In patients with angina in whom obstructive disease in the epicardial coronary arteries has been ruled out by coronary angiography ± FFR, stress perfusion CMR will reclassify the diagnosis leading to changes in treatment (start or stop therapy), improvements in health and economic outcomes, as compared to decisions based standard care (CMR not disclosed).

Design:

We propose that an observational, diagnostic study involving stress CMR will provide information on the prevalence of microvascular disease in a population with anginal symptoms potentially attributable to myocardial ischaemia with no obstructive coronary arteries (INOCA). Each diagnosis is linked to a guideline-directed treatment plan.The potential value of this strategy can only be confirmed if it is associated with patient benefits, which is why we propose a nested, randomised, controlled, double-blind trial of routine disclosure of stress perfusion CMR vs. angiography-guided management

Methods:

Patients undergoing invasive coronary angiography for the investigation of known or suspected angina and who do not have either structural heart disease or a systemic health problem that would explain those symptoms will be invited to participate. Written informed consent is required for participation. Eligibility is further confirmed at the time of the coronary angiogram by exclusion of obstructive (stenosis >70% in a single segment or 50 - 70% in 2 adjacent segments in an artery >2.5 mm, or FFR ≤0.80) coronary artery disease (CAD). Angina symptoms will be confirmed by the completion of validated questionnaires and patients will be invited to attend for a stress perfusion CMR within 3 months of the original coronary angiogram.

On arrival for the CMR, patients will be randomised (1:1) to either the intervention (CMR guided, results disclosed) or blinded control group (CMR undertaken but results not disclosed, standard of care) group.

Trial participants will be blinded to treatment group. The clinicians responsible for on-going care will also be blinded. The design is therefore 'double-blind'. Following the CMR, patients and clinicians will be advised of the diagnosis (endotype) but not the randomised group. The endotype will be informed by the CMR in the intervention group but not in the control group (CMR results not disclosed, angiography-guided). Medical therapy and lifestyle measures are linked to the endotype and informed by contemporary practice guidelines. Therefore, optimal guideline-directed medical care according to the endotype is intended to be the same, regardless of the group allocation.

The sample size is 280 randomised participants. The minimum follow-up duration is 12 months from the last participant recruitment. Follow-up will continued in the longer term including, where feasible, electronic case record linkage.

The primary outcome of the diagnostic study is the reclassification of the initial diagnosis based on findings from the cardiac MRI scan. The primary outcome of the nested randomised trial is the within-subject change at 6 months from baseline for the domains of the Seattle Angina Questionnaire.

Secondary outcomes include other Patient Reported Outcome Measures (PROMS) to describe other aspects of health and wellbeing. These include EQ-5D-5L, Illness perception (Brief IPQ), Treatment satisfaction (TSQM), Duke Activity Status Index (DASI), the International Physical Activity Questionnaire (IPAQ-SF) short-form and a pain questionnaire.

There is preliminary evidence that small vessel disease can be a systemic problem affecting different organs. Whether small vessel disease in the heart might associate with small vessel disease in the brain or retina is unknown. In the CorMicA pilot study, studies of small vessels isolated from biopsies found evidence of endothelial dysfunction and increased responsiveness of the blood vessels to naturally-occurring, constriction-inducing peptides such as endothelin and thromboxane. For these reasons, we plan heart-brain-retina and peripheral vascular substudies.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

280

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • Glasgow
      • East Kilbride, Glasgow, Zjednoczone Królestwo, G75 8RG
        • University Hospital Hairmyres
    • Scotland
      • Ayr, Scotland, Zjednoczone Królestwo, KA6 6D
        • University Hospital Ayr
      • Glasgow, Scotland, Zjednoczone Królestwo, G81 4DY
        • Golden Jubilee National Hospital

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  1. Age ≥18 years
  2. Symptoms of angina or angina-equivalent informed by the Rose Angina questionnaire.
  3. Coronary angiography ≤3 months with a plan for medical management.

Exclusion Criteria:

  1. Obstructive coronary artery disease i.e. a stenosis >70% in a single segment or 50 - 70% in 2 adjacent segments in an artery >2.5 mm, or FFR ≤0.80.
  2. Coronary revascularization by percutaneous coronary intervention or coronary artery bypass graft surgery following the index angiogram.
  3. Prior coronary artery bypass surgery
  4. A diagnosis that would explain the angina e.g. anaemia, aortic stenosis, hypertrophic cardiomyopathy,
  5. Contra-indication to contrast-enhanced CMR e.g. eGFR < 30mL/min/1.73m2.
  6. Contra-indication to intravenous adenosine, i.e. severe asthma; long QT syndrome; second- or third-degree AV block and sick sinus syndrome.
  7. Lack of informed consent.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Diagnostyczny
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Potroić

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Aktywny komparator: Intervention Group

All randomised participants will receive stratified medicine. The subjects will undergo stress perfusion CMR as an adjunct to invasive coronary angiography. The CMR results will be disclosed to the clinician to clarify endotypes and re-evaluate the clinical diagnosis. Linked guideline-directed medical therapy and lifestyle measures will be recommended based on the endotype. The patient and clinicians responsible for downstream care will not be informed of the randomised group but they will be informed of the endotype and linked treatment plan, in the same way as in the Standard Care control group. They will be blinded to the allocated study arm and CMR findings.

The results of the CMR are disclosed, and used to guide management

Pozorny komparator: Standard Care Group

All randomised participants in this arm will receive standard angiography-guided care. The endotype will be determined based on the angiogram and all of the available clinical information. The participants in this group will also undergo stress perfusion CMR but the results will not be disclosed. Management of the patient is as per standard of care, with therapy linked to the diagnosis (endotype). The patient and clinicians responsible for downstream care will not be informed of the randomised group but they will be informed of the endotype and linked treatment plan in the same way as in the Intervention Group. They will be blinded to the allocated study arm and CMR findings.

The results of the CMR are not disclosed, and management is angiography-guided

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Reclassification of the initial diagnosis
Ramy czasowe: Day 1

The reclassification of the initial diagnosis based on invasive management following multi-parametric stress perfusion CMR. The diagnostic groups (endotypes) are:

  1. Anginal symptoms with a myocardial perfusion defect indicative of obstructive CAD;
  2. Anginal symptoms associated with a myocardial perfusion defect indicative of microvascular disease;
  3. Vasospastic angina;
  4. Incidental finding that is actionable e.g. aortic stenosis, cardiomyopathy, lung cancer; or
  5. No clinically significant finding or normal.
Day 1
Seattle Angina Questionnaire (SAQ) Summary Score
Ramy czasowe: 6 months

The 7-item version of the SAQ reflects the frequency of angina (SAQ Angina Frequency score) and the disease-specific effect of angina on patients' physical function (SAQ Physical Limitation score) and quality of life (Quality of Life score) over the previous 4 weeks; these scores are averaged to obtain the SAQ Summary score, which is an overall measure of patients' stable ischaemic heart disease-specific health status. SAQ scores range from 0 to 100, with higher scores indicating less frequent angina, improved function, and better quality of life.

6 months

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Compliance with the protocol
Ramy czasowe: 0-36 months

Assess feasibility of the clinical strategy by measuring compliance with the protocol and, specifically, rate of enrolment, % of patients who drop-out, % of patients who complete the diagnostic MRI protocol.

0-36 months
Integrity of blinding in the Radiology Department and during follow-up
Ramy czasowe: 0-36 months

Assess the integrity and feasibility of blinding by administering patient and clinician questionnaires to determine if both groups have been successfully blinded

0-36 months
Diagnostic utility
Ramy czasowe: 0-36 months

To assess % of patients with a change in diagnosis following disclosure of the cardiac MRI results, and relatedly, the level of certainty reported by the physicians for the diagnosis (diagnostic utility). This will be assessed by a questionnaire completed by the clinician before the MRI, and then again after the MRI results are disclosed.

0-36 months
Clinical Utility
Ramy czasowe: 0-36 months

To assess impact of disclosure of the cardiac MRI results on clinical management (including treatment and investigations). This will be measured by asking clinicians to complete a questionnaire on ongoing clinical management following disclosure of the MRI result

0-36 months
Abnormal myocardial perfusion
Ramy czasowe: Day 1

Assess the prevalence of abnormal blood flow in the heart muscle, as defined by a minimum of 2 adjacent cardiac segments each with ≥50% deficit in myocardial perfusion at peak stress revealed by (1) visual assessment of the dynamic stress perfusion CMR scan and (2) pixel mapping of myocardial blood flow (< 2.0 ml/min/g tissue).

Day 1
Myocardial blood flow
Ramy czasowe: Day 1

Assess the associations between myocardial blood flow (ml/min/g) and invasive measures of coronary function (where available) that might be implicated in the pathophysiology of abnormal coronary vascular function.

Day 1
Myocardial tissue characteristics
Ramy czasowe: Day 1

Assess the correlation between myocardial blood flow (ml/min/g) and myocardial tissue characteristics as revealed by MRI T1- and T2- relaxation times (ms) and extracellular volume fraction.

Day 1
Cardiovascular risk
Ramy czasowe: Day 1

Assess the correlation between cardiovascular risk factors, reflected by validated risk scores (e.g. ASSIGN, JBS3), and myocardial blood flow (ml/min/g) in medically managed patients.

Day 1
Within subject change in myocardial blood flow
Ramy czasowe: 0-12 months

Assess the within-subject change in cardiac MRI findings during 12-months. This will be done by measuring the within-subject change in peak, global, myocardial blood flow over 12 months.

0-12 months
Between-group, within subject change in myocardial blood flow
Ramy czasowe: 0-12 months

Assess the between-group, within-subject change in cardiac MRI findings over 12 months. This outcome will provide insights into the effect of the study intervention on MRI findings. This will be done by measuring the within-subject, between group change in peak, global, myocardial blood flow over 12 months.

0-12 months
Health Status: EQ5D-5L Questionnaire
Ramy czasowe: 0-36 months

The 5-item EuroQol Group EQ5D-5L is a validated questionnaire comprising mobility, self-care, usual activities, pain/discomfort and anxiety/depression to quantitatively assess patient's self-reported health status and will be administered at each study visit.

0-36 months
Health Status: Seattle Angina Questionnaire
Ramy czasowe: 0-36 months

Seattle Angina Questionnaire (SAQ) Summary Score and component scores (Angina Limitation, Angina Stability, Angina Frequency, Treatment Satisfaction and Quality of Life) will be recorded at all study visits.

0-36 months
Health Status: Illness Perception - Brief IPQ
Ramy czasowe: 0-36 months

Brief Illness Perception Questionnaire (Brief IPQ), a nine-item scale designed to rapidly assess the cognitive and emotional representations of illness taken at all study visits.

0-36 months
Health Status: Treatment satisfaction - TSQM
Ramy czasowe: 0-36 months

The 14-item Treatment Satisfaction Questionnaire for Medication (TSQM) is a reliable and valid instrument to assess patients' satisfaction with medication, providing scores on four scales - side effects, effectiveness, convenience and global satisfaction and will administered at all study visits.

0-36 months
Health Status: Duke Activity Status Index
Ramy czasowe: 0-36 months

The 12 point Duke Activity Status Index (DASI) is a validated questionnaire to assess functional capacity and will be administered at all study visits.

0-36 months
Health Status: International Physical Activity Questionnaire- Short Form (IPAQ-SF)
Ramy czasowe: 0-36 months

The 4 point IPAQ-SF is a validated questionnaire to assess functional ability and activuty levels and will be administered at all study visits.

0-36 months
Health Status: Montreal Cognitive Assessment (MOCA)
Ramy czasowe: 0-36 months

The MOCA is an internationally validated 30 point assessment of cognitive function, and will be administered on all study visits.

0-36 months
Correlation between myocardial blood flow and health status
Ramy czasowe: 0-36 months

Assess the correlation between myocardial blood flow (ml/min/g) and health status, as measured by validated questionnaires.

0-36 months
Long term prognosis
Ramy czasowe: 0-20 years

Assess the long-term prognostic significance of between myocardial perfusion (ml/min/g).

0-20 years
Health Outcomes: Major Adverse Cardiovascular Events
Ramy czasowe: 0-20 years

MACE including death, re-hospitalisation for cardiovascular events including myocardial infarction, heart failure, stroke/ TIA, unstable angina and coronary revascularisation. Unscheduled hospital visits for chest pain that have not led to hospital admission will also be documented.

0-20 years
Angina events
Ramy czasowe: 0-3 years

Anginal episodes based on completion of a chest symptoms log and adjudicated by a clinical event committee.

0-3 years
Brain small vessel disease
Ramy czasowe: 0-36 months

Quantify small vessel disease score in the brain using the The STandards for ReportIng Vascular changes on nEuroimaging (STRIVE) guidelines.

0-36 months
Correlation between small vessel disease in the brain and myocardial perfusion
Ramy czasowe: 0-36 months

Assess the correlation between MRI features of small vessel disease in the brain and myocardial perfusion.

0-36 months
Health economics: Inpatients visits
Ramy czasowe: 0-20 years

Health resource utilisation will also be assessed by recording the number of inpatient visits in the follow-up period

0-20 years
Health economics: Cardiac procedures
Ramy czasowe: 0-20 years

Health resource utilisation will also be assessed by recording the number of repeat cardiac procedures performed in the follow up period

0-20 years
Health economics: Medication use
Ramy czasowe: 0-20 years

Health resource utilisation will also be assessed by recording the medication used in the follow up period

0-20 years
Work limitation
Ramy czasowe: 0-36 months

Use the 8-item Work limitation Questionnaire to estimate productivity loss and time lost from work, where appropriate.

0-36 months

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
Small vessel substudy
Ramy czasowe: 0-12 months

Sub-study of small vessel function using myography in arterioles isolated from gluteal skin biopsies.

Standard pharmacological read-outs include the drug concentration required to achieve 50% of the maximum contraction and/or relaxation (wire myography) and structure/function relationships (pressure myography).

0-12 months
Retinal imaging substudy
Ramy czasowe: 0-12 months

Retinal vascular imaging by optical coherence tomography (OCT) to assess for the presence or absence of small vessel disease.

0-12 months

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Współpracownicy

Śledczy

  • Główny śledczy: Colin Berry, MBChB, PhD, Univerisity of Glasgow

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Publikacje ogólne

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

9 lutego 2021

Zakończenie podstawowe (Rzeczywisty)

1 października 2024

Ukończenie studiów (Szacowany)

1 października 2034

Daty rejestracji na studia

Pierwszy przesłany

9 marca 2021

Pierwszy przesłany, który spełnia kryteria kontroli jakości

16 marca 2021

Pierwszy wysłany (Rzeczywisty)

18 marca 2021

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

18 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

15 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • 281128

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

Anonymised data may be shared based on a research agreement

Ramy czasowe udostępniania IPD

After the study has completed

Kryteria dostępu do udostępniania IPD

Bone fide collaboration request

Typ informacji pomocniczych dotyczących udostępniania IPD

  • PROTOKÓŁ BADANIA
  • SOK ROŚLINNY
  • ICF
  • ANALITYCZNY_KOD
  • CSR

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .